|
1125
|
Bexsero
|
Meningococcal disease
|
Neisseria meningitidis
|
Recombinant
|
GSK Vaccines
|
Approved
|
Intramuscular
|
NA
|
NA
|
|
1126
|
Bexsero (In UK)
|
Meningococcal disease
|
Neisseria meningitidis
|
Recombinant
|
GSK Vaccines
|
Approved
|
Intramuscular
|
NA
|
NA
|
|
1127
|
TRUMENBA
|
Meningococcal disease
|
Neisseria meningitidis
|
Recombinant
|
Pfizer (Wyeth Pharmaceuticals)
|
Approved
|
Intramuscular
|
NA
|
NA
|
|
1170
|
rF1V
|
Plague
|
Yersinia pestis
|
Recombinant
|
DynPort Vaccine Company LLC, A GDIT Company
|
Clinical - Phase 2
|
Intramuscular
|
23908395
|
NCT01122784
|
|
1172
|
rBV A/B
|
Botulism
|
Clostridium botulinum
|
Recombinant
|
DynPort Vaccine Company LLC, A GDIT Company
|
Clinical - Withdrawn
|
Intramuscular
|
22269871
|
NCT01940315
|
|
1173
|
VLA15
|
Lyme disease (Lyme borreliosis)
|
Borrelia burgdorferi
|
Recombinant
|
Valneva Austria GmbH and Pfizer
|
Clinical - Phase 2
|
Intramuscular
|
NA
|
NCT04801420
|
|
1174
|
mv rOspA LB
|
Lyme disease (Lyme borreliosis)
|
Borrelia burgdorferi
|
Recombinant
|
Baxalta now part of Shire
|
Clinical - Phase 1, Phase 2
|
Intramuscular
|
NA
|
NCT01504347
|
|
1175
|
Bexsero
|
Gonorrhoea
|
Neisseria gonorrhoeae
|
Recombinant
|
University of North Carolina, Chapel Hill
|
Clinical - Phase 4
|
Intramuscular
|
30551148
|
NCT04094883
|
|
1176
|
CTH522
|
Chlamydia
|
Chlamydia trachomatis
|
Recombinant
|
Statens Serum Institut
|
Clinical - Phase 1
|
Intramuscular
|
31416692
|
NCT02787109
|
|
1180
|
NDV-3
|
Methicillin-Resistant Staphylococcus aureus (MRSA)
|
Staphylococcus aureus
|
Recombinant
|
NovaDigm Therapeutics, Inc.
|
Clinical - Phase 1
|
Intramuscular
|
25489065
|
NCT01273922
|
|
1182
|
V710
|
Methicillin-Resistant Staphylococcus aureus (MRSA)
|
Staphylococcus aureus
|
Recombinant
|
Merck Sharp & Dohme Corp
|
Clinical - Failed
|
Intramuscular
|
25483690
|
NCT00518687
|
|
1185
|
CTH522 (CHLM-02)
|
Trachoma
|
Chlamydia trachomatis
|
Recombinant
|
Statens Serum Institut
|
Clinical - Phase 1
|
Intramuscular
|
31416692
|
NCT03926728
|
|
1200
|
CVD1207
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Recombinant
|
NA
|
Clinical - Phase 1
|
Oral
|
10678904
|
NA
|
|
1203
|
InvaplexAR
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Recombinant
|
U.S. Army Medical Research and Development Command
|
Clinical - Phase 1
|
Intranasal
|
NA
|
NCT02445963
|
|
1205
|
EcSf2a-2
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Recombinant
|
NA
|
Clinical
|
NA
|
NA
|
NA
|
|
1209
|
IC43
|
Pseudomonas infection
|
Pseudomonas aeruginosa
|
Recombinant
|
Valneva Austria GmbH
|
Clinical - Phase 2, Phase 3
|
Intramuscular
|
NA
|
NCT01563263
|
|
1211
|
Recombinant (dsc14CfaE-sCT2/LTB5)
|
E.coli Infections
|
Escherichia coli
|
Recombinant
|
U.S. Army Medical Research and Development Command
|
Clinical - Phase 1
|
Intradermal
|
NA
|
NCT01644565
|
|
1212
|
Recombinant (dscCfaE)
|
E.coli Infections
|
Escherichia coli
|
Recombinant
|
U.S. Army Medical Research and Development Command
|
Clinical - Phase 1
|
Transcutaneous
|
NA
|
NCT01382095
|
|
1215
|
dmLT
|
E.coli Infections
|
Escherichia coli
|
Recombinant
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 1
|
Sublingual
|
NA
|
NCT02052934
|
|
1232
|
CDVAX
|
Clostridium Difficile Infection
|
Clostridium difficile
|
Recombinant
|
Simon M. Cutting
|
Clinical - Terminated
|
Oral
|
NA
|
NCT02991417
|
|
1233
|
IC84
|
Clostridium Difficile Infection
|
Clostridium difficile
|
Recombinant
|
Valneva Austria GmbH
|
Clinical - Phase 1
|
Intramuscular
|
NA
|
NCT01296386
|
|
1234
|
CDIFF Ag
|
Clostridium Difficile Infection
|
Clostridium difficile
|
Recombinant
|
GlaxoSmithKline
|
Clinical - Phase 1
|
Intramuscular
|
NA
|
NCT04026009
|
|
1235
|
VLA84
|
Clostridium Difficile Infection
|
Clostridium difficile
|
Recombinant
|
Valneva Austria GmbH
|
Clinical - Phase 2
|
Intramuscular
|
NA
|
NCT02316470
|
|
1236
|
ID93 + GLA-SE
|
Pulmonary Tuberculosis (TB)
|
Mycobacterium tuberculosis
|
Recombinant
|
Quratis Inc.
|
Clinical - Phase 2
|
Intramuscular
|
NA
|
NCT03806686
|
|
1237
|
VPM1002
|
Pulmonary Tuberculosis (TB)
|
Mycobacterium tuberculosis
|
Recombinant
|
Serum Institute of India Pvt. Ltd.
|
Clinical - Phase 2, Phase 3
|
Intradermal
|
NA
|
NCT03152903
|
|
1365
|
rPA vaccine
|
Anthrax
|
Bacillus anthracis
|
Recombinant
|
PharmAthene UK Limited
|
Clinical - Phase 2
|
NA
|
NA
|
NCT00170469
|
|
1366
|
rPA-102
|
Anthrax
|
Bacillus anthracis
|
Recombinant
|
VaxGen
|
Clinical - Phase 2
|
Intramuscular
|
NA
|
NCT00100724
|
|
1367
|
BW-1010
|
Anthrax
|
Bacillus anthracis
|
Recombinant
|
Blue Willow Biologics
|
Clinical - Phase 1
|
Intranasal
|
NA
|
NCT04148118
|
|
1368
|
PA83-FhCMB
|
Anthrax
|
Bacillus anthracis
|
Recombinant
|
Fraunhofer, Centre for Molecular Biotechnology
|
Clinical - Phase 1
|
NA
|
NA
|
NCT02239172
|
|
1369
|
Px563L
|
Anthrax
|
Bacillus anthracis
|
Recombinant
|
Pfenex, Inc
|
Clinical - Phase 1
|
Intramuscular
|
34544599
|
NCT02655549
|
|
1370
|
RPA563
|
Anthrax
|
Bacillus anthracis
|
Recombinant
|
Pfenex, Inc
|
Clinical - Phase 1
|
Intramuscular
|
NA
|
NCT02655549
|